XELODA - ROCHE

WINNING PRIOR ART FOUND FOR 2 SEPARATE PATHS THAT CAN SHOW THE XELODA PATENT TO BE INVALID!

Article One congratulates our latest winners! Advisors Anonymous and Magnum submitted prior art that can show that the U.S. patent for XELODA is invalid as verified by an independent law firm. The winning references disclose the substitution used to construct the N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine molecule as well as support for why the substitution would be made. Anonymous and Magnum will share the $25,000 Reward for this Study, demonstrating why they belong in the ranks of our Genius Advisors.

 

Study Description:

WINNING PRIOR ART FOUND FOR 2 SEPARATE PATHS THAT CAN SHOW THE XELODA PATENT TO BE INVALID!

Article One congratulates our latest winners! Advisors Anonymous and Magnum submitted prior art that can show that the U.S. patent for XELODA is invalid as verified by an independent law firm. The winning references disclose the substitution used to construct the N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine molecule as well as support for why the substitution would be made. Anonymous and Magnum will share the $25,000 Reward for this Study, demonstrating why they belong in the ranks of our Genius Advisors.

Hoffman LaRoche has sued 2 companies for patent infringement to prevent them from selling a generic version of N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine. The Article One community uncovered references for 2 separate paths that teach the claim elements, why the lead molecule would be selected, what results could be expected from substitutions to the lead molecule, and why a person of ordinary skill in the art at that time would have been motivated to make that change. The proprietary collection is available for license.

Importantly, only a U.S. federal court or the U.S. Patent Office can invalidate a U.S. patent. Article One announces only its own decision for the outcome of Studies based on its analysis of the prior art for purposes of determining winners to its Patent Studies. A court or the Patent Office may disagree with Article One’s decision. While Article One obtains outside counsel verification, Article One’s invalidity position is not a legal opinion.